Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Ulcerative pyoderma gangrenosum is a rare disease with ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
InflaRx was founded in 2007 and maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan. In other recent news, InflaRx N.V. has disclosed post-hoc analyses indicating potential efficacy ...
Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results